Correction to: Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5)

Yuna Suzuki; Wu Wenwen; Tomohiko Ohta; Shin ichi Hayashi

doi:10.1007/s12282-021-01288-z

Correction to: Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5)

Yuna Suzuki, Wu Wenwen, Tomohiko Ohta, Shin ichi Hayashi

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

In the original publication of the article, the funding information should be revised as below. Funding This study was supported by AstraZeneca K.K., Ministry of Education, Culture, Sports, Science and Technology of Japan, and Smoking Research Foundation.

Original language	English
Pages (from-to)	185
Number of pages	1
Journal	Breast Cancer
Volume	29
Issue number	1
DOIs	https://doi.org/10.1007/s12282-021-01288-z
Publication status	Published - 2022 Jan
Externally published	Yes

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s12282-021-01288-z

Fingerprint

Dive into the research topics of 'Correction to: Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5)'. Together they form a unique fingerprint.

Cite this

Correction to : Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5). / Suzuki, Yuna; Wenwen, Wu; Ohta, Tomohiko et al.

In: Breast Cancer, Vol. 29, No. 1, 01.2022, p. 185.

Research output: Contribution to journal › Comment/debate › peer-review

@article{443ffcbb4e584d5a9d1e8ad3b9a50524,

title = "Correction to: Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5)",

abstract = "In the original publication of the article, the funding information should be revised as below. Funding This study was supported by AstraZeneca K.K., Ministry of Education, Culture, Sports, Science and Technology of Japan, and Smoking Research Foundation.",

author = "Yuna Suzuki and Wu Wenwen and Tomohiko Ohta and Hayashi, {Shin ichi}",

note = "Funding Information: Funding This study was supported by AstraZeneca K.K., Ministry of Education, Culture, Sports, Science and Technology of Japan, and Smoking Research Foundation. Publisher Copyright: {\textcopyright} 2021, The Japanese Breast Cancer Society.",

year = "2022",

month = jan,

doi = "10.1007/s12282-021-01288-z",

language = "English",

volume = "29",

pages = "185",

journal = "Breast Cancer",

issn = "1340-6868",

publisher = "Springer Japan",

number = "1",

}

TY - JOUR

T1 - Correction to

T2 - Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5)

AU - Suzuki, Yuna

AU - Wenwen, Wu

AU - Ohta, Tomohiko

AU - Hayashi, Shin ichi

N1 - Funding Information: Funding This study was supported by AstraZeneca K.K., Ministry of Education, Culture, Sports, Science and Technology of Japan, and Smoking Research Foundation. Publisher Copyright: © 2021, The Japanese Breast Cancer Society.

PY - 2022/1

Y1 - 2022/1

N2 - In the original publication of the article, the funding information should be revised as below. Funding This study was supported by AstraZeneca K.K., Ministry of Education, Culture, Sports, Science and Technology of Japan, and Smoking Research Foundation.

AB - In the original publication of the article, the funding information should be revised as below. Funding This study was supported by AstraZeneca K.K., Ministry of Education, Culture, Sports, Science and Technology of Japan, and Smoking Research Foundation.

UR - http://www.scopus.com/inward/record.url?scp=85113207631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85113207631&partnerID=8YFLogxK

U2 - 10.1007/s12282-021-01288-z

DO - 10.1007/s12282-021-01288-z

M3 - Comment/debate

C2 - 34420190

AN - SCOPUS:85113207631

VL - 29

SP - 185

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 1

ER -

Correction to: Molecular targeted drugs resistance impairs double-strand break repair and sensitizes ER-positive breast cancer to PARP inhibitors (Breast Cancer, (2022), 29, 1, (77-91), 10.1007/s12282-021-01282-5)

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this